In:
Pathology International, Wiley, Vol. 68, No. 11 ( 2018-11), p. 596-604
Kurzfassung:
The clinicopathological implications of ovarian cancer immunoreactive antigen domain containing 2 (OCIAD2) in lung adenocarcinoma were investigated. The expression of OCIAD2 in 191 surgically resected lung adenocarcinomas was examined using immunohistochemistry. OCIAD2 expression was quantified using the H‐score and dichotomized as high or low. High OCIAD2 protein expression was significantly correlated with vascular invasion ( P = 0.0018), lymphatic permeation ( P = 0.049), T factor ( P = 0.0024), and pathological stage ( P = 0.0003). High OCIAD2 expression was significantly associated with poorer overall survival (OS) ( n = 191, P = 0.0325). In peripheral‐type lung adenocarcinomas ( n = 161), high OCIAD2 expression was significantly associated with both poorer OS ( P = 0.0214) and poorer disease‐free survival ( P = 0.0496). Adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) showed weaker OCIAD2 expression than invasive adenocarcinoma. Among small adenocarcinomas measuring 2 cm or less in greatest dimension classified according to the Noguchi's classification ( n = 79), invasive adenocarcinomas showed significantly higher OCIAD2 expression than non‐invasive adenocarcinomas ( P = 0.0007). Interestingly, OCIAD2 was expressed heterogeneously even within a tumor, and its expression was higher in areas of invasion than in areas of in situ spread. Our results suggest that OCIAD2 could be a useful prognostic biomarker of lung adenocarcinoma.
Materialart:
Online-Ressource
ISSN:
1320-5463
,
1440-1827
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2018
ZDB Id:
2008574-6
